Third-generation TKIs, exemplified by osimertinib for EGFR-mutated disease and lorlatinib for ALK-rearranged NSCLC, currently represent the pinnacle of intracranial control, achieving superior objective response rates and remarkably prolonged intracranial progression-free survival [40,68]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.